Does CBD Work For Neuropathic Pain

The authors of this review summarized the efficacy and safety data of cannabinoid-based drugs to assess their potential for treating neuropathic pain. Researchers analyzed the safety and efficacy of various cannabis-based drugs, while also assessing their impact on pain scores. They found that cannabinoids, particularly CBD/THC-based drugs, have been demonstrated to be effective in the treatment and management of neuropathic pain.

Researchers sought to understand the impact Sativex, a cannabinoid-based THC/CBD oromucosal spray, may have on helping to manage neuropathic pain. They found that Sativex is both efficacious and well-tolerated in the treatment of a variety of neuropathic conditions. They conclude that if their results can be replicated, Sativex shows great promise as a potential treatment for neuropathic pain.

This review examines modern studies on the effects that THC and CBD may have on sleep, while also reporting new information on the impact of sleep in the context of neuropathic pain. They found that a 1:1 THC/CBD-based medicine, Sativex, improved subjective sleep parameters in patients suffering from a variety of pain conditions. While additional long-term safety studies are recommended, Sativex has been demonstrated to be effective and well-tolerated in studies extending as far as four years.

For this study, researchers evaluated the effect of Sativex on pain and allodynia in patients with peripheral neuropathic pain. They observed improvements in the patient's Neuropathic Pain Scale composite scores, sleep NRS, dynamic allodynia, punctate allodynia, Pain Disability Index, as well as the Patient's Global Impression of Change. Not only that, but these results were maintained without dose escalation or toxicity concerns for an additional 52 weeks in an open-label extension study.

Researchers found that exogenous non-psychoactive cannabinoids such as CBD have been repeatedly demonstrated to be effective in a range of experimental neuropathic pain models, with evidence mounting for their therapeutic use in treating human neuropathic conditions. The authors recommend additional research go into these cannabinoids for the potential as a novel treatment for managing neuropathic pain.

In this review, the authors investigate the potential use of cannabinoids in the treatment and management of symptoms associated with neuropathic orofacial pain. They note the analgesic properties of cannabinoids, and that multiple studies have demonstrated their safety and efficacy in the treatment of neuropathic pain. The authors recommend additional research into the development of a cannabinoid-based drug for the treatment of neuropathic pain.

Researchers examine the antihyperalgesic effect of CBD could be mediated by CB1, CB2, or TRPV1 receptors. Using rat models, they found that modulation of the TRPV1 receptor influenced this effect, with little observed in the other receptors. In their conclusion, they note that the TRPV1 receptor may be a molecular target of CBDs antihyperalgesic effect.

This study sought to create a case for the development of cannabinoid-based drugs in the treatment of neuropathic pain. Using rat models, researchers found that formulations containing ratios of varying cannabinoids, as opposed to single cannabinoid drugs, offered better antinociceptive efficacy in neuropathic pain. These results demonstrate the therapeutic potential of cannabinoid-based medicines in the treatment and management of neuropathic pain.

For this experiment, researchers test two non-psychoactive cannabinoids, CBD and CBC, for their antinociceptive effect. Using rat models, the team found that both CBD and CBC were effective in inducing antinociceptive responses. In their results, the authors conclude that CBD and CBC stimulated antinociception and caused analgesia, showing potential as a therapeutic agent using multiple mechanisms of action.

The authors of this study report that the administration of CBD and related synthetic analogs significantly suppress chronic inflammation and neuropathic pain without causing analgesic tolerance in rat models. Their findings suggest that cannabinoid-based formulations may be useful in suppressing chronic pain. They also conclude that cannabinoids may be a novel class of therapeutic agents in the treatment and management of chronic pain.

This review explores the endocannabinoid system and cannabinoid-based medications, as well as their mechanisms of action. Through their work, the authors highlight the repeated demonstrated efficacy and safety of using cannabinoid-based medicines in the treatment and management of neuropathic pain and associated conditions. The authors recommend further clinical trials to evaluate potential applications of cannabinoid-based medications as novel therapeutic drugs for helping to manage pain.

In this study, researchers compare the efficacy of a THC:CBD extract against a THC extract in relieving pain in patients facing advanced cancer. In their findings, the THC:CBD extract performed significantly better than the THC extract alone in improving the suffering of patients. The authors conclude that a THC:CBD extract is effective and well-tolerated for relieving pain in patients with advanced cancer not mitigated by opioids.

The author of this article reviews a 2011 study on the effects of administering CBD to treat neuropathy caused by chemotherapy. The study’s results showed that CBD pretreatment before chemotherapy effectively prevented abnormal pain development, which may be permanent. There was no evidence of neuropathy even after pretreatment had ended. The author notes that while these results are promising, additional research is needed to evaluate the effects and underlying mechanisms using human models.

This study by a drug screening company reviews potential nonadherence to patients prescribed opioids. Their findings indicated that consumers of cannabis actually ended up not taking their opioid medications, through the testing of urine samples that detected cannabinoids but not opioids. Their results suggest that cannabis users find effective and well-tolerated pain relief as opposed to those prescribed opioids.

Central neuropathic pain is one of the most common symptoms caused by any dysfunction in the nervous system. CBD was tested as a potential method for reducing pain without adverse side effects. CBD was shown to be an effective treatment option even after two years of doses, as there was no evidence of increased tolerance.

Researchers wanted to take a deeper look at the anti-inflammatory and immunomodulatory effects of CBD. CBD was administered to rat models daily for two weeks, which resulted in very promising results. The team noted reduced hyperalgesia, which they attributed to a vanilloid antagonist. As such, they believe CBD has the potential to be therapeutic for chronic pain conditions.

The research concluded CBD provides a protective effect against Paclitaxel induced neurotoxicity in cancer patients. The study indicated CBD doesn’t harm either nervous system function or chemotherapy efficacy. The team also assessed the impact of CBD on several distinct factors, including place conditioning and cancer cell viability.

This review of the available evidence suggests CBD and the endocannabinoid system could play an integral role in pain treatment. Not only do clinical trials show CBD is well-tolerated, but a growing number of researchers agree on their value. Repeated randomized trials have shown CBD based medications are safe and effective in treating central and peripheral neuropathic pain.

A comprehensive review of all the plant-based medicine which has had both preclinical and human clinical trials conducted about their anxiolytic-like effect. An analysis of over 1500 papers identified 21 plants which had been adequately tested, with one of the most successful of these plants found to be CBD enriched Cannabis species.

A study of mice concluded CBD has significant anti-inflammatory effects. The researchers also saw evidence that the expression of the GPR55 receptor was improved after starting on CBD. Treatment with CBD was shown to significantly decrease the levels of several inflammation-related chemicals in test subjects.

Researchers concluded CBD significantly reduces discomfort and pain, in part, due to the interaction between two substances, PEA and anandamide. According to tests, they “act synergistically, reducing pain responses 100-fold more potently than each compound alone”.